AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
3.380
+0.090 (2.74%)
Nov 22, 2024, 4:00 PM EST - Market closed
AC Immune Revenue
AC Immune had revenue of 25.49M CHF in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to 40.97M, up 4,097,200.00% year-over-year. In the year 2023, AC Immune had annual revenue of 14.80M with 276.14% growth.
Revenue (ttm)
40.97M CHF
Revenue Growth
+4,097,200.00%
P/S Ratio
6.72
Revenue / Employee
254,491 CHF
Employees
161
Market Cap
334.42M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cerus | 176.23M |
Kamada | 158.38M |
Spok Holdings | 137.71M |
Sanara MedTech | 78.06M |
AVITA Medical | 60.04M |
Delcath Systems | 22.64M |
Nyxoah | 5.67M |
Q32 Bio | -14.66M |
ACIU News
- 8 days ago - AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients - Benzinga
- 4 months ago - AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 - GlobeNewsWire
- 4 months ago - AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward - Seeking Alpha
- 4 months ago - AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease - GlobeNewsWire
- 6 months ago - AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 - GlobeNewsWire
- 6 months ago - Alzheimer's vaccine licensing deal boosts AC Immune - Market Watch
- 6 months ago - AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 6 months ago - AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease - Business Wire